Recent blog posts
NCT07697599 REGN-7508 Venous Thromboembolism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07697599 REGN-7508 Venous Thromboembolism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07697599 clinical trial report covering REGN-7508, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07699237 Carboplatin Recurrent Lung Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07699237 Carboplatin Recurrent Lung Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07699237 clinical trial report covering Carboplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07699211 Dalbavancin Hydrochloride Endocarditis, Bacterial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07699211 Dalbavancin Hydrochloride Endocarditis, Bacterial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07699211 clinical trial report covering Dalbavancin Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262667 Girocitinib Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262667 Girocitinib Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262667 clinical trial report covering Girocitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262411 Recombinant human C1 esterase inhibitor (Chengdu Institute of Biological Product Hereditary Angioedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262411 Recombinant human C1 esterase inhibitor (Chengdu Institute of Biological Product Hereditary Angioedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262411 clinical trial report covering Recombinant human C1 esterase inhibitor (Chengdu Institute of Biological Product, Phase 2, endpoints, sponsor, geog
Read →
CTR20262653 YH01 Head and Neck Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262653 YH01 Head and Neck Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262653 clinical trial report covering YH01, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262692 Susineridine Analgesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262692 Susineridine Analgesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262692 clinical trial report covering Susineridine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262684 Qingyan Lihou Capsule Acute pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262684 Qingyan Lihou Capsule Acute pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262684 clinical trial report covering Qingyan Lihou Capsule, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262699 H889A Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262699 H889A Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262699 clinical trial report covering H889A, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262787 KH-607 Depressive Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262787 KH-607 Depressive Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262787 clinical trial report covering KH-607, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262768 20-valent Pneumococcal Conjugate Vaccine(Pfizer) Pneumonia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262768 20-valent Pneumococcal Conjugate Vaccine(Pfizer) Pneumonia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262768 clinical trial report covering 20-valent Pneumococcal Conjugate Vaccine(Pfizer), Phase 3, endpoints, sponsor, geography, readout timing and develo
Read →
NCT07712523 QY-201 Nonsegmental vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07712523 QY-201 Nonsegmental vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07712523 clinical trial report covering QY-201, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →